Literature DB >> 27521448

Impact of Blood-Brain Barrier Integrity on Tumor Growth and Therapy Response in Brain Metastases.

Matthias Osswald1,2, Jonas Blaes1,2, Yunxiang Liao1,2, Gergely Solecki1,2, Miriam Gömmel1,2, Anna S Berghoff1,2, Laurent Salphati3, Jeffrey J Wallin4, Heidi S Phillips4, Wolfgang Wick1,2, Frank Winkler5,2.   

Abstract

PURPOSE: The role of blood-brain barrier (BBB) integrity for brain tumor biology and therapy is a matter of debate. EXPERIMENTAL
DESIGN: We developed a new experimental approach using in vivo two-photon imaging of mouse brain metastases originating from a melanoma cell line to investigate the growth kinetics of individual tumor cells in response to systemic delivery of two PI3K/mTOR inhibitors over time, and to study the impact of microregional vascular permeability. The two drugs are closely related but differ regarding a minor chemical modification that greatly increases brain penetration of one drug.
RESULTS: Both inhibitors demonstrated a comparable inhibition of downstream targets and melanoma growth in vitro In vivo, increased BBB permeability to sodium fluorescein was associated with accelerated growth of individual brain metastases. Melanoma metastases with permeable microvessels responded similarly to equivalent doses of both inhibitors. In contrast, metastases with an intact BBB showed an exclusive response to the brain-penetrating inhibitor. The latter was true for macro- and micrometastases, and even single dormant melanoma cells. Nuclear morphology changes and single-cell regression patterns implied that both inhibitors, if extravasated, target not only perivascular melanoma cells but also those distant to blood vessels.
CONCLUSIONS: Our study provides the first direct evidence that nonpermeable brain micro- and macrometastases can effectively be targeted by a drug designed to cross the BBB. Small-molecule inhibitors with these optimized properties are promising agents in preventing or treating brain metastases in patients. Clin Cancer Res; 22(24); 6078-87. ©2016 AACRSee related commentary by Steeg et al., p. 5953. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2016        PMID: 27521448     DOI: 10.1158/1078-0432.CCR-16-1327

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  48 in total

1.  Drug delivery to melanoma brain metastases: Can current challenges lead to new opportunities?

Authors:  Gautham Gampa; Shruthi Vaidhyanathan; Jann N Sarkaria; William F Elmquist
Journal:  Pharmacol Res       Date:  2017-06-17       Impact factor: 7.658

2.  Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases.

Authors:  Franziska Maria Ippen; Julia Katharina Grosch; Megha Subramanian; Benjamin Macfarlane Kuter; Bianca M Liederer; Emile G Plise; Joana Liliana Mora; Naema Nayyar; Stephen Paul Schmidt; Anita Giobbie-Hurder; Maria Martinez-Lage; Scott L Carter; Daniel P Cahill; Hiroaki Wakimoto; Priscilla Kaliopi Brastianos
Journal:  Neuro Oncol       Date:  2019-11-04       Impact factor: 12.300

3.  Multiple protocadherins are expressed in brain microvascular endothelial cells and might play a role in tight junction protein regulation.

Authors:  Christina Dilling; Norbert Roewer; Carola Y Förster; Malgorzata Burek
Journal:  J Cereb Blood Flow Metab       Date:  2017-01-17       Impact factor: 6.200

Review 4.  A Blazing Landscape: Neuroinflammation Shapes Brain Metastasis.

Authors:  Hila Doron; Tobias Pukrop; Neta Erez
Journal:  Cancer Res       Date:  2019-01-24       Impact factor: 12.701

Review 5.  Advances in decoding breast cancer brain metastasis.

Authors:  Chenyu Zhang; Dihua Yu
Journal:  Cancer Metastasis Rev       Date:  2016-12       Impact factor: 9.264

6.  Brain Distribution of a Novel MEK Inhibitor E6201: Implications in the Treatment of Melanoma Brain Metastases.

Authors:  Gautham Gampa; Minjee Kim; Nicholas Cook-Rostie; Janice K Laramy; Jann N Sarkaria; Linda Paradiso; Louis DePalatis; William F Elmquist
Journal:  Drug Metab Dispos       Date:  2018-02-02       Impact factor: 3.922

Review 7.  The blood-brain barrier and blood-tumour barrier in brain tumours and metastases.

Authors:  Costas D Arvanitis; Gino B Ferraro; Rakesh K Jain
Journal:  Nat Rev Cancer       Date:  2019-10-10       Impact factor: 60.716

Review 8.  Foe or friend? Janus-faces of the neurovascular unit in the formation of brain metastases.

Authors:  Imola Wilhelm; Csilla Fazakas; Kinga Molnár; Attila G Végh; János Haskó; István A Krizbai
Journal:  J Cereb Blood Flow Metab       Date:  2017-09-18       Impact factor: 6.200

9.  Mechanisms of enhanced drug delivery in brain metastases with focused ultrasound-induced blood-tumor barrier disruption.

Authors:  Costas D Arvanitis; Vasileios Askoxylakis; Yutong Guo; Meenal Datta; Jonas Kloepper; Gino B Ferraro; Miguel O Bernabeu; Dai Fukumura; Nathan McDannold; Rakesh K Jain
Journal:  Proc Natl Acad Sci U S A       Date:  2018-08-27       Impact factor: 11.205

10.  Nanoparticles Containing a Combination of a Drug and an Antibody for the Treatment of Breast Cancer Brain Metastases.

Authors:  Emily A Wyatt; Mark E Davis
Journal:  Mol Pharm       Date:  2020-01-14       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.